Forward Thinking: Novel Cancer Cell Therapy Approaches

Forward Thinking: Novel Cancer Cell Therapy Approaches

Watch our video series featuring academia, pharma, and biotech pioneers reviewing novel approaches in cancer cell therapy. Explore various modalities such as CAR-T, CAAR, and gamma delta T cells as we take you on a journey from discovery to safety. Absorb key takeaways such as avoiding and navigating complex obstacles from those who have already mastered the expedition through leveraging the latest tools such as bioinformatics, to drive discovery and maximize your ROI.

By completing the form, you will gain access to exclusive presentations under the oncology umbrella spanning the following topics:

Identification of Target Candidates for Pancreatic Adenocarcinoma Immunotherapy (32:48)
Olaf Hardt, PhD, Senior Manager, Research & Development, Miltenyi 
Considerations for Data Generation Strategy in CAR T Development (7:43)
Max Bylesjo, PhD, Technical Director, Fios Genomics 
Cell Therapy for Cancer: Allogeneic Approaches for the Next Generation of CAR T (31:28)
Dave Gilham, PhD, Chief Scientific Officer, Celyad 
Impacts of Multi-Valent Targeting of Immunotherapy in Oncology (40:07)
Ed McGowan, PhD, Director Discovery, Charles River  
In vitro Pharmacology and Safety for Cell Therapy IND-Enabling Studies (30:57)
Gemma Moiset, PhD, Group Leader, Charles River Nederlands
Key Animal Model Designs for Drug Resistant Immunotherapy of Glioblastoma (34:20)
Lawrence Lamb, PhD, Executive Vice President & Chief Scientific Officer, In8Bio
CAAR-T:  Beyond Oncology Applications (25:14)
Jinmin Lee, PhD, Associate Principal Scientist, Cabaletta Bio
Panel: Cell Therapies Beyond CAR T (32:27)
Ed McGowan, PhD, Director Discovery, Charles River   
Lawrence Lamb, PhD, Executive Vice President & Chief Scientific Officer, In8Bio 
Olaf Hardt, PhD, Senior Manager, Research & Development, Miltenyi  
Jinmin Lee, PhD, Associate Principal Scientist, Cabaletta Bio